Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
cbdMD Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
YCBD
American
2833
https://www.cbdmd.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for cbdMD Inc
cbdMD Reduces Year over Year Net Loss from Operations by $3.0 Million
- Feb 13th, 2024 9:10 pm
cbdMD, Inc. to Host Conference Call to Discuss First Quarter of Fiscal 2024 Results
- Feb 8th, 2024 9:05 pm
cbdMD Welcomes Vice President of Wholesale Sales, Joe Baghadjian- Paving the Way for Future Growth
- Feb 8th, 2024 3:10 pm
cbdMD Announces Financing of $1,250,000
- Feb 2nd, 2024 10:00 pm
cbdMD Unveils THCV+CBG Energy Softgels, Ushering in a New Era of Wellness Solutions
- Jan 31st, 2024 3:56 pm
cbdMD Launches into Sprouts Farmers Market, Bringing Premium CBD Gummies to 175 Stores Nationwide
- Jan 18th, 2024 4:50 pm
cbdMD Reduces Year over Year Net Loss from Operations by $55.8 Million
- Dec 22nd, 2023 9:06 pm
cbdMD, Inc. to Host Conference Call to Discuss September 30, 2023 Fourth Quarter and Fiscal Year 2023 Results
- Dec 20th, 2023 5:47 pm
cbdMD Wins Awards in Two Categories at Prestigious Best in Biz Awards
- Dec 14th, 2023 4:03 pm
cbdMD Announces Cancellation of Special Meeting
- Oct 25th, 2023 9:50 pm
cbdMD Announces Historic Partnership with FIFA-Affiliated Costa Rican Soccer Team
- Oct 5th, 2023 1:00 pm
cbdMD Announces Adjournment of Special Meeting
- Sep 22nd, 2023 9:02 pm
Breaking Barriers: cbdMD's Research Validates Safe CBD Upper Dose
- Sep 22nd, 2023 1:58 pm
Shareholders are Encouraged to Vote Well in Advance of the Proxy Deadline of 1:00 p.m. (Eastern time) on September 22, 2023
- Sep 14th, 2023 4:48 pm
Paw CBD Wins 2023 'Dog Hip & Joint Product of the Year' Pet Innovation Award
- Aug 25th, 2023 1:00 pm
cbdMD, Inc. Suspends Monthly Dividend Payment on Its Series A Cumulative Convertible Preferred Stock
- Aug 22nd, 2023 12:30 pm
cbdMD Responds to Congressional Request for Information (RFI) on Regulation of CBD Products
- Aug 18th, 2023 6:23 pm
Paw CBD Recognized With “Dog Hip & Joint Product Of The Year” Award From Pet Innovation
- Aug 17th, 2023 12:00 pm
cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million
- Aug 10th, 2023 8:48 pm
cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2023 Results
- Aug 7th, 2023 2:00 pm
Scroll